Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    PR Mobile Headlines    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory    |    Private Branding
All Press Releases for August 21, 2008 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Cultrex Mouse Laminin I Now Qualified "PathClear "
Trevigen adds mouse Laminin I to PathClear designated products for research Involving cancer cell characterization and behavior. 
x-small text small text medium text large text


    /24-7PressRelease/ - GAITHERSBURG, MD, August 21, 2008 - Cancer researchers are finding more uses for mouse laminin I derived from EHS Sarcoma. Cancer cell characterization and modulation of behavior in response to putative attractants or inhibitors underlie important aspects of cancer research. Cell adhesion, migration, growth and differentiation are all studied using mouse laminin I along with other specialized proteins available from Trevigen, Inc.

Proteins derived from the EHS sarcoma have been found to harbor murine viruses such as LDEV, which may not be detected by MAP testing. The presence of these viruses could affect experimental results and cause incorrect conclusions. The reason that viruses may be present but not detected is that traditional manufacturing approaches do not remove all pathogens. Viruses may be present in low enough concentrations to be beneath the threshold of detection for the standard MAP Assays.

To solve these problems Trevigen has developed a new (patent applied for) manufacturing process which preserves both the biochemical integrity and the biological performance of mouse laminin I while eliminating the problem of low concentration viruses. In addition to the standard sterility, mycoplasma, endotoxin and MAP tests, the mouse laminin I is tested by PCR and cleared of a battery of 31 mouse pathogens including LDEV. This eliminates concern that contaminating agents may interfere and cause erroneous test results. Mouse laminin I produced by the new process is rigorously tested for contaminating organisms and designated PathClear .

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes - Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

PathClear BME, Mouse laminin I antibody, and other specialty proteins are also available separately from Trevigen. Visit http://www.trevigen.com or contact us at 1800-873-8443 or info@trevigen.com for more information.

# # #


Read more Press Releases from Trevigen Inc.:
Other Press Release Headlines:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Trevigen Inc.
Trevigen, Inc.

Business Development
8405 Helgerman Court
Gaithersburg, MD
USA 20877
Voice: 1.800.873.8443
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.